Top

Acta Neurologica Belgica

Published in:

01-12-2020 | Insulins | Original article

Serum seladin-1 levels in diabetes mellitus and Alzheimer's disease patients

Authors: Attila Önmez, Merve Alpay, Serkan Torun, İ. Ethem Şahin, Kürşad Öneç, Yıldız Değirmenci

Published in: Acta Neurologica Belgica | Issue 6/2020

Abstract

Background

Diabetes mellitus (DM) has been shown to increase the risk of Alzheimer’s disease (AD). Downregulation of selective Alzheimer’s disease indicator-1 (seladin-1) occurs in the cerebral regions affected by AD. However, inconsistent results have been reported for the relationship between seladin-1 levels and AD. The effect of DM on serum seladin-1 levels in AD is unknown. The present study is aimed to investigate serum seladin-1 levels in diabetic and non-diabetic patients with AD.

Methods

Forty-six patients with AD and 25 healthy volunteers over 65 years of age were included in this study. The patients were divided into three groups—those with AD only, those with DM and AD, and control groups. Demographic characteristics and serum seladin-1 levels were compared among the groups.

Results

There was no statistically significant difference in seladin-1 levels in the AD only group compared to the control group (p = 0.376). However, seladin-1 levels were significantly lower in the DM and AD group compared to the AD only and control groups (p = 0.002, p = 0.001; respectively). Negative correlations were present between seladin-1 and fasting glucose, postprandial glucose, HbA1c, and insulin (p < 0.05; all).

Conclusion

Decreased serum seladin-1 values in the presence of DM and inverse correlations with diabetic parameters in patients with AD, together with a non-significant difference from the control group, suggests that seladin-1 may be altered only in the presence of DM in patients with AD. Lower serum seladin-1 levels may also play a role in the pathogenesis of AD in patients with DM.

Satman I, Yilmaz T, Sengül A, Salman S, Salman F, Uygur S, Bastar I, Tütüncü Y, Sargin M, Dinççag N (2002) Population-based study of diabetes and risk characteristics in Turkey: results of the Turkish diabetes epidemiology study (TURDEP). Diabetes Care 25(9):1551–1556CrossRefPubMed

Cho N, Shaw J, Karuranga S, Huang Y, da Rocha FJ, Ohlrogge A, Malanda B (2018) IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 138:271–281CrossRefPubMed

Melmed S, Polonsky KS, Larsen PR, Kronenberg HM (2015) Williams textbook of endocrinology. Elsevier Health Sciences, Amsterdam

Ott A, Stolk R, Van Harskamp F, Pols H, Hofman A, Breteler M (1999) Diabetes mellitus and the risk of dementia: the Rotterdam study. Neurology 53(9):1937–1937CrossRefPubMed

Kivipelto M, Helkala E-L, Laakso MP, Hänninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A (2001) Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 322(7300):1447–1451CrossRefPubMedPubMedCentral

Luchsinger JA, Tang M-X, Shea S, Mayeux R (2004) Hyperinsulinemia and risk of Alzheimer disease. Neurology 63(7):1187–1192CrossRefPubMed

Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA (2004) Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 61(5):661–666CrossRefPubMed

Janson J, Laedtke T, Parisi JE, O’Brien P, Petersen RC, Butler PC (2004) Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53(2):474–481CrossRefPubMed

Derakhshan F, Toth C (2013) Insulin and the brain. Curr Diabetes Rev 9(2):102–116PubMed

10.

Leibson CL, Rocca WA, Hanson V, Cha R, Kokmen E, Obrien P, Palumbo P (1997) Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol 145(4):301–308CrossRefPubMed

11.

Hoyer S (2002) The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update. J Neural Transm 109(3):341–360CrossRefPubMed

12.

Kandimalla R, Thirumala V (1863) Reddy PH (2017) Is Alzheimer's disease a type 3 diabetes? A critical appraisal. Biochimica et Biophysica Acta (BBA) Mol Basis Dis 5:1078–1089

13.

Andersson HC, Kratz L, Kelley R (2002) Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay. Am J Med Genet 113(4):315–319CrossRefPubMed

14.

Iivonen S, Hiltunen M, Alafuzoff I, Mannermaa A, Kerokoski P, Puoliväli J, Salminen A, Helisalmi S, Soininen H (2002) Seladin-1 transcription is linked to neuronal degeneration in Alzheimer’s disease. Neuroscience 113(2):301–310CrossRefPubMed

15.

Wu C, Miloslavskaya I, Demontis S, Maestro R, Galaktionov K (2004) Regulation of cellular response to oncogenic and oxidative stress by seladin-1. Nature 432(7017):640–645. https://doi.org/10.1038/nature03173CrossRefPubMed

16.

Tedde A, Cellini E, Bagnoli S, Sorbi S, Peri A (2008) Mutational screening analysis of DHCR24/seladin-1 gene in Italian familial Alzheimer's disease. Am J Med Genet Part B Neuropsychiatr Genet 147(1):117–119CrossRef

17.

Liang WS, Dunckley T, Beach TG, Grover A, Mastroeni D, Ramsey K, Caselli RJ, Kukull WA, McKeel D, Morris JC (2008) Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. Physiol Genomics 33(2):240–256CrossRefPubMed

18.

Sharpe LJ, Wong J, Garner B, Halliday GM, Brown AJ (2012) Is seladin-1 really a selective Alzheimer's disease indicator? J Alzheimers Dis 30(1):35–39CrossRefPubMed

19.

Giannini S, Benvenuti S, Luciani P, Manuelli C, Cellai I, Deledda C, Pezzatini A, Vannelli GB, Maneschi E, Rotella CM, Serio M, Peri A (2008) Intermittent high glucose concentrations reduce neuronal precursor survival by altering the IGF system: the involvement of the neuroprotective factor DHCR24 (seladin-1). J Endocrinol 198(3):523–532. https://doi.org/10.1677/joe-07-0613CrossRefPubMed

20.

Kazkayasi I, Ismail MA, Parrado-Fernandez C, Bjorkhem I, Pekiner C, Uma S, Cedazo-Minguez A, Burul-Bozkurt N (2016) Lack of insulin results in reduced seladin-1 expression in primary cultured neurons and in cerebral cortex of STZ-induced diabetic rats. Neurosci Lett 633:174–181. https://doi.org/10.1016/j.neulet.2016.09.018CrossRefPubMed

21.

Greeve I, Hermans-Borgmeyer I, Brellinger C, Kasper D, Gomez-Isla T, Behl C, Levkau B, Nitsch RM (2000) The human DIMINUTO/DWARF1 homolog seladin-1 confers resistance to Alzheimer's disease-associated neurodegeneration and oxidative stress. J Neurosci 20(19):7345–7352CrossRefPubMedPubMedCentral

22.

Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6(8):734–746. https://doi.org/10.1016/s1474-4422(07)70178-3CrossRefPubMed

23.

Association AD (2020) 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2020. Diabetes Care 43(Supplement 1):14–31CrossRef

24.

Salas IH, Weerasekera A, Ahmed T, Callaerts-Vegh Z, Himmelreich U, D'Hooge R, Balschun D, Saido TC, De Strooper B, Dotti CG (2018) High fat diet treatment impairs hippocampal long-term potentiation without alterations of the core neuropathological features of Alzheimer disease. Neurobiol Dis 113:82–96. https://doi.org/10.1016/j.nbd.2018.02.001CrossRefPubMed

25.

Crameri A, Biondi E, Kuehnle K, Lutjohann D, Thelen KM, Perga S, Dotti CG, Nitsch RM, Ledesma MD, Mohajeri MH (2006) The role of seladin-1/DHCR24 in cholesterol biosynthesis, APP processing and Abeta generation in vivo. EMBO J 25(2):432–443. https://doi.org/10.1038/sj.emboj.7600938CrossRefPubMedPubMedCentral

26.

Martiskainen H, Paldanius KMA, Natunen T, Takalo M, Marttinen M, Leskela S, Huber N, Makinen P, Bertling E, Dhungana H, Huuskonen M, Honkakoski P, Hotulainen P, Rilla K, Koistinaho J, Soininen H, Malm T, Haapasalo A, Hiltunen M (2017) DHCR24 exerts neuroprotection upon inflammation-induced neuronal death. J Neuroinflam 14(1):215. https://doi.org/10.1186/s12974-017-0991-6CrossRef

27.

Benvenuti S, Saccardi R, Luciani P, Urbani S, Deledda C, Cellai I, Francini F, Squecco R, Rosati F, Danza G, Gelmini S, Greeve I, Rossi M, Maggi R, Serio M, Peri A (2006) Neuronal differentiation of human mesenchymal stem cells: changes in the expression of the Alzheimer's disease-related gene seladin-1. Exp Cell Res 312(13):2592–2604. https://doi.org/10.1016/j.yexcr.2006.04.016CrossRefPubMed

28.

Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW (2004) Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci USA 101(7):2173–2178. https://doi.org/10.1073/pnas.0308512100CrossRefPubMedPubMedCentral

29.

Kazkayasi I, Parrado-Fernandez C, Björkhem I, Pekiner C, Uma S, Cedazo-Minguez A, Burul-Bozkurt N (2016) Lack of insulin results in reduced seladin-1 expression in primary cultured neurons and in cerebral cortex of STZ-induced diabetic rats. Neurosci Lett 633:174–181CrossRefPubMed

30.

Giannini S, Benvenuti S, Luciani P, Manuelli C, Cellai I, Deledda C, Pezzatini A, Vannelli G, Maneschi E, Rotella C (2008) Intermittent high glucose concentrations reduce neuronal precursor survival by altering the IGF system: the involvement of the neuroprotective factor DHCR24 (Seladin-1). J Endocrinol 198(3):523–532CrossRefPubMed

31.

Suzuki R, Lee K, Jing E, Biddinger SB, McDonald JG, Montine TJ, Craft S, Kahn CR (2010) Diabetes and insulin in regulation of brain cholesterol metabolism. Cell Metab 12(6):567–579CrossRefPubMedPubMedCentral

32.

Sarajarvi T, Haapasalo A, Viswanathan J, Makinen P, Laitinen M, Soininen H, Hiltunen M (2009) Down-regulation of seladin-1 increases BACE1 levels and activity through enhanced GGA3 depletion during apoptosis. J Biol Chem 284(49):34433–34443. https://doi.org/10.1074/jbc.M109.036202CrossRefPubMedPubMedCentral

33.

Hsu C-C, Wahlqvist ML, Lee M-S, Tsai H-N (2011) Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. J Alzheimer's Dis 24(3):485–493CrossRef

34.

Wiciński M, Wódkiewicz E, Słupski M, Walczak M, Socha M, Malinowski B, Pawlak-Osińska K (2018) Neuroprotective activity of sitagliptin via reduction of neuroinflammation beyond the incretin effect: focus on Alzheimer’s disease. BioMed Res Int 2018:6091014CrossRefPubMedPubMedCentral

Title: Serum seladin-1 levels in diabetes mellitus and Alzheimer's disease patients
Authors: Attila Önmez
Merve Alpay
Serkan Torun
İ. Ethem Şahin
Kürşad Öneç
Yıldız Değirmenci
Publication date: 01-12-2020
Publisher: Springer International Publishing
Keywords: Insulins
Alzheimer's Disease
Alzheimer's Disease
Diabetes
Insulins
Published in: Acta Neurologica Belgica / Issue 6/2020
Print ISSN: 0300-9009
Electronic ISSN: 2240-2993
DOI: https://doi.org/10.1007/s13760-020-01393-4

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Serum seladin-1 levels in diabetes mellitus and Alzheimer's disease patients

Abstract

Background

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2020

Anxiety is associated with increased risk for atrial cardiopathy

Recte faciendo, neminem timeas: in ruling out the worst cause of non-traumatic headache

Giant tumefactive perivascular spaces: an incidental finding

Phenotypic and genotypic features of patients diagnosed with ALS in the city of Sakarya, Turkey

A childhood-onset nemaline myopathy caused by novel heterozygote variants in the nebulin gene with literature review

Multidisciplinary approach to Fabry disease: from the eye of a neurologist